Skip to main content

Table 4 Baseline infecting intra-abdominal pathogens and uropathogens (MITT/cIAI population and mMITT/cUTI population)

From: Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

Pathogen,a n (%)

cIAI

cUTI

Diabetes

n = 65

No diabetes

n = 741

Diabetes

n = 133

No diabetes

n = 667

Gram-negative aerobes

46 (70.8)

613 (82.7)

127 (95.5)

637 (95.5)

 Enterobacteriaceae

45 (69.2)

577 (77.9)

126 (94.7)

613 (91.9)

   Escherichia coli

37 (56.9)

488 (65.9)

99 (74.4)

530 (79.5)

   Klebsiella pneumoniae

0 (0.0)

70 (9.4)

14 (10.5)

44 (6.6)

Pseudomonas aeruginosa

0 (0.0)

68 (9.2)

1 (0.8)

22 (3.3)

Gram-positive aerobes

38 (58.5)

406 (54.8)

6 (4.5)

42 (6.3)

Enterococcus faecalis

16 (24.6)

79 (10.7)

4 (3.0)

34 (5.1)

E. faecium

0 (0.0)

74 (10.0)

0 (0.0)

5 (0.7)

Staphylococcus aureus

0 (0.0)

27 (3.6)

2 (1.5)

4 (0.6)

Gram-negative anaerobes

24 (36.9)

267 (36.0)

0 (0.0)

NA

Bacteroides spp

23 (35.4)

228 (30.8)

0 (0.0)

NA

Gram-positive anaerobes

7 (10.8)

92 (12.4)

0 (0.0)

NA

  1. cIAI complicated intra-abdominal infection, cUTI complicated urinary tract infection, MITT microbiologic intention-to-treat, mMITT microbiologic modified intention-to-treat, NA, not applicable
  2. aPatients could have had multiple infecting pathogens at baseline